GlassScriptPhysician profile
William F Ball
NPI 1194797936
$8,869.71
in general payments reported to CMS, 2019-2025
45 companies · $832 in 2025
The $832 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,020 · 2020: $1,086 · 2021: $1,792 · 2022: $1,622 · 2023: $1,357 · 2024: $1,160 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,349.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,302.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,139.95 | 2019-2024 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $842.92 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $416.64 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $403.41 | 2020-2025 | Spravato, Xarelto |
| Esperion Therapeutics, INC. | $394.93 | 2021-2024 | Nexletol |
| Pfizer INC. | $382.59 | 2019-2025 | |
| Glaxosmithkline, LLC. | $336.21 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $271.65 | 2019-2024 | |
| Lilly USA, LLC | $255.27 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Teva Pharmaceuticals USA, INC. | $255.19 | 2019-2022 | |
| Mannkind Corporation | $207.72 | 2019-2021 | |
| Allergan, INC. | $205.82 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $198.54 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $195.11 | 2022-2024 | Rexulti, Abilify Maintena |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $174.32 | 2022-2025 | Kyphon Express II Kyphopak Tray, Synchromedii |
| Astellas Pharma US INC | $157.35 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.11 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $139.48 | 2019-2022 | |
| Abbott Laboratories | $137.27 | 2021-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $135.25 | 2021-2023 | Eliquis |
| Amarin Pharma, INC. | $118.80 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $110.64 | 2020-2021 | |
| Biogen, INC. | $105.21 | 2021-2023 | Spinraza |
| Lundbeck LLC | $88.75 | 2023 | Rexulti |
| Phathom Pharmaceuticals, INC. | $81.40 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $81.25 | 2022 | |
| Sanofi-Aventis U.S. LLC | $79.41 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $67.94 | 2023-2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.22 | 2019-2020 | |
| Dexcom, INC. | $53.91 | 2024 | Dexcom G6 Transmitter |
| Si-Bone, INC. | $46.65 | 2022-2024 | |
| Kowa Pharmaceuticals America, INC. | $36.78 | 2020-2022 | |
| Sanofi Pasteur INC. | $31.94 | 2023 | |
| Pulmonx Corporation | $27.38 | 2024 | Chartis Catheter, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Axsome Therapeutics, INC. | $23.63 | 2023 | Sunosi |
| Genentech USA, INC. | $21.31 | 2021 | |
| Exact Sciences Corporation | $21.28 | 2023 | Cologuard Collection Kit |
| Actelion Pharmaceuticals US, INC. | $20.90 | 2021 | |
| Optinose US, INC. | $19.66 | 2021 | |
| Ucb, INC. | $19.49 | 2020 | |
| Arbor Pharmaceuticals, INC. | $17.16 | 2019 | |
| Horizon Therapeutics Plc | $14.30 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.06 | 2020 | |
| Depuy Synthes Sales INC. | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.